Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa
Raphael Schiffmann(Texas Christian University), Pedro E. Huertas(Harvard–MIT Division of Health Sciences and Technology), Bruce A. Barshop(University of California San Diego), Atul Mehta(University College London), Derek Blankenship(Renal Research Institute), Robert D. Steiner(University of Wisconsin–Madison), Michael L. West(Dalhousie University), Kathy Nicholls(Melbourne Health), Nitin Nair(Takeda (United States)), Markus Ries(Heidelberg University), Michael Beck(Eastern Illinois University), David A. Amato, Joe T.R. Clarke(Dalhousie University), Rick Martin(Takeda (United States)), William J. Rhead(Children's Hospital of Wisconsin)
Cited by 27
Related Papers
Metabolomics Reveals Signature of Mitochondrial Dysfunction in Diabetic Kidney Disease
|Journal of the American Society of Nephrology|2013|578
Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
|New England Journal of Medicine|2016|555
Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy
|European Journal of Pediatrics|2007|535
Characterization of Classical and Nonclassical Fabry Disease: A Multicenter Study
|Journal of the American Society of Nephrology|2016|421
Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy
|Nephrology Dialysis Transplantation|2009|366